Anti-tumor necrosis factor-alpha therapy is associated with less frequent mood and anxiety disorders in patients with rheumatoid arthritis

Basit Öğe Kaydı
dc.contributor.authorUguz, Faruk
dc.contributor.authorAkman, Cemal
dc.contributor.authorKucuksarac, Seher
dc.contributor.authorTufekci, Osman
dc.date.accessioned2020-03-26T17:37:53Z
dc.date.available2020-03-26T17:37:53Z
dc.date.issued2009
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractThe purpose of the present study was to examine the current prevalence of mood and anxiety disorders, and factors related to mood and anxiety disorders in patients with rheumatoid arthritis (RA). The study sample included 83 consecutive patients with RA who were admitted to a rheumatology outpatient clinic. Diagnoses of psychiatric disorders were determined using the Structured Clinical Interview for DSM-IV (SCID-I). To assess physical disability and disease activity, the Health Assessment Questionnaire and the Disease Activity Score, respectively, were used. The prevalence of any mood or any anxiety disorder was 43.4%. The two most common psychiatric diagnoses were major depression (21.7%) and generalized anxiety disorder (16.9%). Mood and anxiety disorders were unrelated to sociodemographic features, disease-related factors, and medications for RA except anti-tumor necrosis factor-alpha (TNF-alpha). These disorders, however, were identified less frequently in patients with RA receiving anti-TNF-alpha drugs compared to patients who did not receive such medications. Patients with RA frequently have mood and anxiety disorders, and anti-TNF-alpha drugs may be useful for the mental status of these patients.en_US
dc.identifier.doi10.1111/j.1440-1819.2008.01905.xen_US
dc.identifier.endpage55en_US
dc.identifier.issn1323-1316en_US
dc.identifier.issue1en_US
dc.identifier.pmid19154212en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage50en_US
dc.identifier.urihttps://dx.doi.org/10.1111/j.1440-1819.2008.01905.x
dc.identifier.urihttps://hdl.handle.net/20.500.12395/23289
dc.identifier.volume63en_US
dc.identifier.wosWOS:000262513400008en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWILEY-BLACKWELL PUBLISHING, INCen_US
dc.relation.ispartofPSYCHIATRY AND CLINICAL NEUROSCIENCESen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectanxietyen_US
dc.subjectdepressionen_US
dc.subjectrheumatoid arthritisen_US
dc.subjecttumor necrosis factor-alphaen_US
dc.titleAnti-tumor necrosis factor-alpha therapy is associated with less frequent mood and anxiety disorders in patients with rheumatoid arthritisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu